Trial Profile
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs GB 001 (Primary)
- Indications Allergic asthma; Asthma
- Focus Therapeutic Use
- Acronyms LEDA
- Sponsors Gossamer Bio
- 03 Mar 2022 Results published in the Chest
- 13 Oct 2020 According to a Gossamer Bio media release, the company will host a conference call and live audio webcast to discuss the results from this trial.
- 13 Oct 2020 According to a Gossamer Bio media release, full results from LEDA will be submitted for future presentation at an upcoming scientific meeting.